CIK 0001894562 · <br>Emerging growth company
Prime Medicine, Inc.
Sign in to watch- Ticker
- PRME
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-465-0013
- Business address
- 60 FIRST ST., CAMBRIDGE, MA, 02141
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 8-K Event Results of operations · Other events
- 8-K Event Executive or director change
- DEF 14A Proxy Proxy Statement
- PRE 14A Proxy Proxy Statement (Preliminary)
- 4 Open-market buy 10% owner bought 21,000 shares at $2.52 ($52,830)
- 4 Open-market buy 10% owner bought 21,000 shares at $2.16 ($45,402)
- 4 Open-market buy 10% owner bought 21,000 shares at $1.49 ($31,196)
- 4 Open-market buy 10% owner bought 21,000 shares at $1.60 ($33,590)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Shareholder vote results
- 4 Open-market buy Chief Business Officer bought 20,000 shares at $1.19 ($23,790)
- 4 Open-market buy Chief Technical Officer bought 100,000 shares at $1.13 ($113,000)
Page 4 of 16 · 302 filings